About Bioline  All Journals  Testimonials  Membership  News  Donations

International Journal of Reproductive BioMedicine
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences of Yazd
ISSN: 1680-6433
EISSN: 2008-2177
Vol. 3, No. 1, 2005, pp. 14-18
Bioline Code: rm05003
Full paper language: English
Document type: Research Article
Document available free of charge

International Journal of Reproductive BioMedicine, Vol. 3, No. 1, 2005, pp. 14-18

 en A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles
Ashrafi, Mahnaz; Moini, Ashraf; Mohammadzadeh, Afsaneh; Ezabadi, Zahra; Zafarani, Fatemeh & Baghestani, Ahmad Reza


Background: Polycystic ovarian syndrome (PCOS) patients are prone to premature LH surge and ovarian hyperstimulation syndrome (OHSS). Long GnRH analogue protocol and GnRH antagonist protocol are two methods utilized for induction ovulation in patients undergoing IVF/ICSI.
Objective: The aim of this study was to compare the effects of GnRH agonists and antagonists in PCOS patients.
Materials and Methods: A total of 60 PCOS patients under 35 years old were enrolled in this study. The patients have no history of thyroid disorder and hyperprolactinemia. All patients received OCP (LD) before starting the treatment. Then patients randomly divided into two groups. The agonist group underwent standard long GnRH analogue protocol. In antagonist group, HMG (150 IU/day) was started from third day of cycle. Then GnRH antagonist (0.25mg) was administered from 6th day after HMG initiation (LH≤5 IU/ml) to the day of HCG injection. Follicular development monitored by vaginal ultra sonography and serum estradiol measurement.
Results: There were no significant differences in age, duration of infertility, BMI, number of HMG ampules, number of follicles≥18mm, serum estradiol level on 6th day of HMG initiation and HCG injection time, fertilization and pregnancy rate between two groups. However there were significant differences regarding duration of treatment, duration of HMG usage, LH level at the initiation of HMG, OHSS rate and number of Metaphase II oocytes between two groups (p<0.05).
Conclusion: Usage of the GnRH antagonist may have more advantages such as the shorter duration of treatment and less gonadotrophin requirement. Furthermore, the incidence of OHSS can be reduced in GnRH antagonist comparing to agonist. For decreasing the risk of OHSS and abortion rate, we recommend long term use of OCP before starting the treatment.

PCOS , GnRH agonist, GnRH antagonist , OHSS, IVF, ICSI.

© Copyright 2005 - Iranian Journal of Reproductive Medicine
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 10-Sep-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil